JP2008538919A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538919A5
JP2008538919A5 JP2008508906A JP2008508906A JP2008538919A5 JP 2008538919 A5 JP2008538919 A5 JP 2008538919A5 JP 2008508906 A JP2008508906 A JP 2008508906A JP 2008508906 A JP2008508906 A JP 2008508906A JP 2008538919 A5 JP2008538919 A5 JP 2008538919A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
human
binding
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008508906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538919A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/014182 external-priority patent/WO2006118772A2/en
Publication of JP2008538919A publication Critical patent/JP2008538919A/ja
Publication of JP2008538919A5 publication Critical patent/JP2008538919A5/ja
Pending legal-status Critical Current

Links

JP2008508906A 2005-04-29 2006-04-14 ＦｃＲｎ抗体およびその使用 Pending JP2008538919A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67641205P 2005-04-29 2005-04-29
PCT/US2006/014182 WO2006118772A2 (en) 2005-04-29 2006-04-14 Fcrn antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2008538919A JP2008538919A (ja) 2008-11-13
JP2008538919A5 true JP2008538919A5 (OSRAM) 2009-07-09

Family

ID=37105335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008508906A Pending JP2008538919A (ja) 2005-04-29 2006-04-14 ＦｃＲｎ抗体およびその使用

Country Status (5)

Country Link
US (1) US20100266530A1 (OSRAM)
EP (1) EP1879920A2 (OSRAM)
JP (1) JP2008538919A (OSRAM)
CA (1) CA2606378A1 (OSRAM)
WO (1) WO2006118772A2 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524664A (ja) * 2006-01-25 2009-07-02 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 自己／アロ免疫疾患の治療のための抗−ｆｃｒｎ抗体
US20100166734A1 (en) * 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
EP2195028A2 (en) 2007-09-18 2010-06-16 The Jackson Laboratory Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
TWI593423B (zh) * 2008-04-25 2017-08-01 戴埃克斯有限公司 Ｆｃ受體結合蛋白
AU2015200004B2 (en) * 2008-04-25 2017-02-16 Bioverativ Therapeutics Inc. Antibodies against fcrn and use thereof
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
US8232067B2 (en) 2009-05-29 2012-07-31 Brigham & Women's Hospital, Inc. Disrupting FCRN-albumin interactions
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
PH12013502378A1 (en) * 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
ZA201506407B (en) * 2013-03-15 2018-11-28 Affibody Ab New polypeptides
EP2970406B1 (en) 2013-03-15 2017-12-13 Affibody AB New polypeptides
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
JP6620094B2 (ja) * 2013-11-26 2019-12-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答を調節するための組成物および方法
CA2934644C (en) 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
EP3804745A1 (en) * 2014-04-25 2021-04-14 The Brigham and Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
EP3134733B1 (en) * 2014-04-25 2020-10-14 The Brigham and Women's Hospital, Inc. Assay and method for treating subjects with immune-mediated diseases
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
NZ726089A (en) * 2014-04-30 2017-12-22 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases
US10323066B2 (en) 2014-09-17 2019-06-18 Affibody Ab Neonatal Fc receptor binding dimer and methods of use
HK1251483A1 (zh) * 2015-05-12 2019-02-01 Synt免疫公司 人源化亲和力成熟的抗fcrn抗体
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
EP3802590A2 (en) 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
MA53903A (fr) 2018-10-16 2021-08-25 UCB Biopharma SRL Méthode de traitement de la myasthénie grave
EP3980063A1 (en) 2019-06-07 2022-04-13 Argenx BVBA Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
KR20220148804A (ko) 2020-01-08 2022-11-07 아르젠엑스 비브이 천포창 장애의 치료 방법
JP2023531451A (ja) * 2020-06-17 2023-07-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 遺伝子療法患者の治療のための組成物及び方法
EP4384548A4 (en) * 2021-08-13 2024-11-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING FCRN AND THEIR USES
CN119013290A (zh) * 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子
JP2025522251A (ja) 2022-05-30 2025-07-15 ハナル バイオファーマ カンパニーリミテッド 安定性が向上した抗ＦｃＲｎ抗体またはこの抗原結合断片
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6992234B2 (en) * 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
EP1660128A4 (en) * 2003-08-08 2009-01-21 Univ New York State Res Found ANTI-CORR ANTI-BODIES FOR THE TREATMENT OF AUTO / ALLO-IMMUNE DISORDERS
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions

Similar Documents

Publication Publication Date Title
JP2023090710A5 (OSRAM)
CN105980407B (zh) 单克隆抗tk1抗体
ES2532410T3 (es) Identificación de antígenos asociados a tumores para diagnóstico y terapia
JP2014528695A5 (OSRAM)
JP2020534830A5 (OSRAM)
JP2014113150A5 (OSRAM)
JP2009100745A5 (OSRAM)
RU2014120536A (ru) Белки специфического связывания и их применения
RU2012147960A (ru) Trail r2-специфические мультимерные скаффолды
JP2013506428A5 (OSRAM)
CA2947660A1 (en) Anti-b7-h3 antibodies and diagnostic uses thereof
RU2009137784A (ru) Человеческое опухолеспецифическое моноклональное антитело
JP2016505634A5 (OSRAM)
JP2022531454A5 (OSRAM)
JP2020516603A5 (OSRAM)
Kroenke et al. Immunogenicity Risk Assessment for Multi-specific Therapeutics: Immunogenicity Risk Assessment for Multi-specific Therapeutics
JP6081699B2 (ja) Ｉｌ−２８ｂの分析方法
JP2011501946A5 (OSRAM)
JP2014515600A5 (OSRAM)
JP2022512672A5 (OSRAM)
EP2736926A1 (en) Use of the antibody i-3859 for the detection and diagnosis of cancer
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
JP2017536821A5 (OSRAM)
JP5821198B2 (ja) 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法
JP2008515388A5 (OSRAM)